| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | OPNT | Common Stock | Options Exercise | $20K | +2K | +24.67% | $10.00 | 10.1K | Sep 21, 2021 | Direct | |
| transaction | OPNT | Common Stock | Sale | -$1.44K | -60 | -0.59% | $24.07 | 10K | Sep 21, 2021 | Direct | F1, F2 |
| transaction | OPNT | Common Stock | Sale | -$18.6K | -771 | -7.67% | $24.12 | 9.28K | Sep 21, 2021 | Direct | F1, F3 |
| transaction | OPNT | Common Stock | Options Exercise | $18.3K | +1.83K | +19.77% | $10.00 | 11.1K | Sep 22, 2021 | Direct | |
| transaction | OPNT | Common Stock | Sale | -$18.4K | -735 | -6.62% | $25.02 | 10.4K | Sep 22, 2021 | Direct | F1, F4, F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | OPNT | Stock Option (right to buy) | Options Exercise | $0 | -2K | -52.16% | $0.00 | 1.83K | Sep 21, 2021 | Common Stock | 2K | $10.00 | Direct | F6, F7 |
| transaction | OPNT | Stock Option (right to buy) | Options Exercise | $0 | -1.83K | -100% | $0.00* | 0 | Sep 22, 2021 | Common Stock | 1.83K | $10.00 | Direct | F6, F7 |
| Id | Content |
|---|---|
| F1 | The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. |
| F2 | The shares were sold to cover the $10 exercise price of the vested stock options. The net shares of 25, after selling to cover the exercise price, will be held by the Reporting Person. |
| F3 | The shares were sold to cover the $10 exercise price of the vested stock options. The net shares of 1,144, after selling to cover the exercise price, will be held by the Reporting Person. |
| F4 | The shares were sold to cover the $10 exercise price of the vested stock options. The net shares of 1,099, after selling to cover the exercise price, will be held by the Reporting Person. |
| F5 | This transaction was executed in multiple trades at prices ranging from $24.52 to $25.04. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| F6 | The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. |
| F7 | On November 4, 2016, the reporting person was granted an option to purchase 35,000 shares of Common Stock. The options vest as follows: (i) 11,667 share upon the up listing of the Issuer to The NASDAQ Stock Market (which occurred on August 29, 2017); (ii) 11,667 shares upon the cumulative funding of the Issuer in excess of $5,000,000 by institutional investors, commencing May 5, 2016 (which performance criteria was met on December 13, 2016); and (iii) 11,666 shares upon the first submission of a New Drug Application ("NDA") to the FDA for one of Issuer's products by either the Issuer or an Issuer licensee. |